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ABSTRACT
The cap-dependent translation is frequently deregulated in a variety of
cancers associated with tumor progression. However, the molecular basis of the
translation activation for metastatic progression of cancer remains largely elusive.
Here, we demonstrate that activation of cap-dependent translation by silencing the
translational repressor 4E-BP1 causes cancer epithelial cells to undergo epithelialmesenchymal transition (EMT), which is associated with selective upregulation of the
EMT inducer Snail followed by repression of E-cadherin expression and promotion of
cell migratory and invasive capabilities as well as metastasis. Conversely, inhibition
of cap-dependent translation by a dominant active mutant 4E-BP1 effectively
downregulates Snail expression and suppresses cell migration and invasion.
Furthermore, dephosphorylation of 4E-BP1 by mTORC1 inhibition or directly targeting
the translation initiation also profoundly attenuates Snail expression and cell motility,
whereas knockdown of 4E-BP1 or overexpression of Snail significantly rescues the
inhibitory effects. Importantly, 4E-BP1-regulated Snail expression is not associated
with its changes in the level of transcription or protein stability. Together, these
findings indicate a novel role of 4E-BP1 in the regulation of EMT and cell motility
through translational control of Snail expression and activity, and suggest that
targeting cap-dependent translation may provide a promising approach for blocking
Snail-mediated metastatic potential of cancer.

INTRODUCTION

Bcl-2 and survivin, is strongly dependent on the eIF-4E.
Consequently, these oncogenic mRNAs are selectively
and disproportionately affected by eIF4E availability and
are sensitive to the alteration in the levels of eIF4E [2,
3]. Overexpression of eIF4E is frequently observed in
a variety of human cancers. In addition, another major
mechanism for regulation of eIF4E function is involved in
the eIF4E-binding proteins, 4E-BPs. 4E-BP1 (the major
epithelial cell form) is a member of the 4E-BP family
that represses translation by competing with eIF4G for
binding to eIF4E, thereby preventing formation of the
eIF4F complex. In cancer cells, however, 4E-BP1 is
frequently hyperphosphorylated by its upstream oncogenic
signals such as PI3K/AKT and RAS/RAF/MEK/ERK

The cap-dependent translation is a process by
which most capped mRNAs are translated into proteins.
This process is limited by translation initiation, a step
controlled by the eIF4F complex at the level of ribosomal
recruitment. The eIF4F complex is assembled by the
translation initiation factor eIF-4E that binds to the 5’cap structure of mRNAs, the scaffolding protein eIF4G
and the RNA helicase eIF4A [1]. Emerging evidence
indicates that translation of certain key oncogenic mRNAs
bearing long and highly structured 5’-untranslated regions
(UTR), such as those encoding proliferation- and survivalpromoting proteins including cyclins, VEGF, c-Myc,
www.impactjournals.com/oncotarget
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pathways, which causes 4E-BP1 disassociation from
eIF4E and thus inactivates 4E-BP1 function and increases
the level of free eIF4E. The mTOR kinase complex 1
(mTORC1), a downstream target of both AKT and ERK
signaling [4, 5], is a master regulator of eIF4E-initiated
cap-dependent translation by phosphorylating 4E-BP1
on Thr37 and Thr46 that act as priming sites for its
subsequent phosphorylation on Ser65 and Thr70 [6].
Hyperphosphorylation of 4E-BP1 or reduction of 4E-BP1
expression is associated with malignant progression and
poor prognosis [3, 7-9], whereas dephosphorylation of
4E-BP1 has been identified as an important biomarker for
predicting response to anti-cancer therapy [10, 11]. These
findings have indicated that deregulation of 4E-BP1controlled cap-dependent translation can contribute to
cancer progression and support the development of agents
that target 4E-BP1 phosphorylation or eIF-4E.
Snail (Snail1) is a zinc-finger transcription factor
that functions as a key transcriptional repressor in
inhibiting E-cadherin expression [12, 13]. E-cadherin is
a transmembrane glycoprotein that mediates epithelial
intercellular junctions. Downregulation of E-cadherin
is a hallmark of epithelial-mesenchymal transition
(EMT) during embryonic development, a process also
exploited by invasive cancer cells [14, 15]. During EMT,
epithelial tumor cells lose their epithelial polarity and
cell-cell adhesion and gain mesenchymal phenotypes
with increased migratory and invasive capabilities. It has
long been believed that EMT is initiated at the advanced
stage of tumor progression and is a prerequisite for tumor
cell dissemination and metastasis [14, 15]. Numerous
experimental systems showed that Snail represses
E-cadherin expression and induces EMT in different type
of cancer cells, indicating that Snail plays a fundamental
role in EMT and cancer metastasis [14, 15]. Indeed, there
is a considerable inverse correlation between Snail and
E-cadherin expression in a variety of epithelial tumors.
Overexpression of Snail or reduced E-cadherin expression
correlates with higher tumor grade, nodal metastasis and
tumor recurrence, and predicts poor clinical outcomes in
patients with various cancers [12-15]. Snail expression is
induced by a wide range of signaling pathways including
TGFβ, Notch and Wnt pathways and hypoxia stress [16].
Phosphorylation of Snail by GSK3β and PAK1 plays
an important role in regulation of its stability, cellular
localization and function [17, 18]. However, little is
known about whether Snail is regulated at the level of
translation.
In the present study, we demonstrate that activation
of cap-dependent translation by loss of 4E-BP1 function in
cancer cells selectively upregulates Snail expression and
enhances its functions on EMT, cell migration/invasion
and metastasis. Our study uncovers an important aspect of
translational regulation of Snail in controlling cell motility
and metastatic potential of cancer.

www.impactjournals.com/oncotarget

Reduction of 4E-BP1 expression induces EMT,
upregulates Snail expression and promotes cancer
cell migration, invasion and metastasis
4E-BP1 expression has been shown to be inversely
correlated with tumor progression in colorectal, breast
and other cancers [8-10]. To investigate the functional
importance and molecular basis of 4E-BP1-regulated
cap-dependent translation in cancer progression, we
generated HCT116 colon cancer cell derivatives with
stable knockdown of 4E-BP1 expression by shRNA. As
compared to the morphology of HCT116 cells or HCT116
cells expressing control shRNA under a light microscope,
we surprisingly observed that knockdown of 4E-BP1
expression caused HCT116 cells acquired fibroblasticlike characteristics, as they demonstrated a more elongated
morphology and a scattered density, whereas the isogenic
controls or parental cells exhibited higher degree of
adherence between neighboring cells (Figure 1A). Similar
results were also observed in silencing 4E-BP1 expression
in DLD1 colon cancer cells (Supplementary Figure 1A).
The observed alterations are characteristic features of
EMT. The loss of E-cadherin is considered to be the most
fundamental event during EMT [14, 15]. Intriguingly, we
found that cells (HCT116, DLD1, SW480, BT474) with
stable knockdown of 4E-BP1 expression demonstrated
a marked reduction in the level of E-cadherin protein
(Figure 1B and Supplementary Figure 1B). To understand
how E-cadherin was downregulated by 4E-BP1
knockdown, we determined the expression of several
key transcriptional factors known to facilitate EMT by
repression of E-cadherin. Remarkably, the expression of
Snail, a direct transcriptional repressor of E-cadherin,
was dramatically upregulated in those cells with 4E-BP1
knockdown (Figure 1B and Supplementary Figure 1B).
In contrast, expression of other E-cadherin transcriptional
repressors such as Slug (Snail2) and Twist was unaffected.
Emerging evidence indicates that induction of EMT by
Snail contributes cells granted with motility and invasion
capacities [14, 15]. We thus examined the effect of 4E-BP1
knockdown on cell migration and invasion using Boyden
chamber assays as we described previously [19]. As shown
in Figure 1C, D, HCT116 cells with 4E-BP1 knockdown
exhibited a three- to five-fold increase in both migratory
and invasive capacities compared with the control cells.
Similar results were also obtained in three other colon
cancer cell lines (DLD1, HT29, SW480) and three
breast cancer cell lines (MDA-MB-231, MDA-MB-468,
BT474) in which 4E-BP1 gene was silenced (Figure
1D, migration data not shown). To determine whether
the increased migratory and invasive abilities of cancer
cells by 4E-BP1 knockdown facilitate cancer metastasis,
6016
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we used an experimental liver metastasis model of colon
cancer in vivo as we described previously [19]. Luciferase
and GFP-labeled HCT116 cells with stable 4E-BP1
knockdown were injected intrasplenically into athymic
nude mice. Formation of liver metastasis was assessed
by bioluminescent and fluorescent imaging. Compared
to the HCT116 cells expressing control shRNA, silencing
4E-BP1 expression markedly promoted liver metastases
in mice (Figure 1E, F). Collectively, these results suggest
that 4E-BP1 loss selectively upregulates Snail protein
expression for EMT induction and subsequently enhances
cancer cell migration and invasion as well as metastasis.

translation in the regulation of Snail expression and
cell migration and invasion, 4E-BP1 wild-type (wt)
and its mutant 4E-BP1-4A, in which the four known
phosphorylation sites (T37, T46, S65, T70) were replaced
with alanine were ectopically expressed in HCT116
cells. We showed previously that the mutant 4E-BP14A cannot be phosphorylated and binds constitutively to
eIF4E, thus inhibits cap-dependent translation, whereas
expression of 4E-BP1 wt had no such effects due to its
hyperphosphorylation in HCT116 cells [11]. As compared
to 4E-BP1 wt and vector control, expression of the
dominant active 4E-BP1-4A mutant profoundly repressed
expression of Snail but not Slug and Twist (Figure 2A),
and additionally inhibited cell migration and invasion
as we showed previously [19]. Similar results were also
obtained in MDA-157 breast cancer cells by expression
of the active 4E-BP1-4A mutant (Supplementary Figure
2). To further confirm the role of 4E-BP1 in regulation
of Snail activity, 4E-BP1 wt and 4A were re-expressed
in HCT116-4E-BP1 knockdown cells. Consistent with

Dephosphorylated 4E-BP1 inhibits Snail
expression and cancer cell migration and invasion
Loss of 4E-BP1 expression or hyperphosphorylation
of 4E-BP1 is known to lead to activation of cap-dependent
translation [1]. To ascertain the role of cap-dependent

Figure 1: Silencing of 4E-BP1 induces EMT, upregulates Snail expression, and enhances cancer cell migration, invasion
and metastasis. (A) For morphological comparison, HCT116 cells alone or with stable expression of control (Ctrl) shRNA or 4E-BP1

shRNA cells were photographed using a light microscope. Scale bar = 200 µm. (B) HCT116 cells alone or with stable expression of Ctrl
shRNA or 4E-BP1 shRNA were immunoblotted with the indicated antibodies. (C) Transwell migration analysis of HCT116 cells with stable
expression of Ctrl shRNA or 4E-BP1 shRNA over 6 h. The results represent the mean number of migrated cells per field ± S.E.M. (n=3).
Scale bar = 500 µm. (D) The invasive ability of various cancer cell lines with stable expression of Ctrl shRNA or 4E-BP1 shRNA. The
results are expressed as the fold change of cell invasion in Sh 4E-BP1 cells relative to the Sh Ctrl cells and presented as means ± S.E.M.
(n=3). (E) Bioluminescence and GFP images of liver metastasis in athymic nude mice injected intrasplenically with HCT116-Luc/GFP
cells expressing Ctrl shRNA or 4E-BP1 shRNA at week 3 post-injection. (F) Quantitative analysis of bioluminescence in liver metastasis
as shown in (E) (n=6 mice/group). * P < 0.02 for Sh 4E-BP1 versus Sh Ctrl.
www.impactjournals.com/oncotarget
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our previous findings [11] and the results as indicated
above, expressed 4E-BP1-4A bound constitutively to
eIF4E-mRNA cap complex and markedly inhibited
Snail expression attendant with a dramatic increase in
the level of E-cadherin and suppression of cell invasion
(Figure 2B, C and D). In contrast, 4E-BP1 wt was highly
phosphorylated at the four phosphorylation sites; only
slightly bound to eIF4E-mRNA cap complex; and thus
had much less inhibitory effect on Snail expression and
cell invasion than those induced by 4E-BP1-4A. These
data suggest that the phosphorylation status of 4E-BP1
is associated with its function on the regulation of Snail
expression and its activity.
The mTOR kinase forms two distinct functional
complexes, mTORC1 and mTORC2. mTORC1 is a master
regulator of cap-dependent translation by phosphorylation
of 4E-BP1, whereas mTORC2 regulates AKT activity
through phosphorylation of AKT on Ser473 [20].
Rapamycin is a modest inhibitor of mTORC1 activity
and mTOR kinase inhibitors are much more effective
than rapamycin in inhibiting 4E-BP1 phosphorylation
[21, 22]. Using a clinical-grade ATP-site mTOR kinase
inhibitor AZD8055 [23], we explored whether mTORC1
inhibition also suppresses Snail expression and cancer cell
migration and invasion. As shown in Figure 3A, B and
Supplementary Figure 3, AZD8055 effectively inhibited
phosphorylation of 4E-BP1 at the four phosphorylation
sites in the three tested cell lines (HCT116, MDA-MB-468

and MDA-MB-231). Inhibition of 4E-BP1 phosphorylation
in these cells was associated with downregulation of Snail
expression accompanied by an increase in E-cadherin
expression upon AZD8055 exposure within 24 h (Figure
3A). In contrast, AZD8055 had no effect on the expression
of other E-cadherin regulators, Slug and Twist, or a
recently reported Snail regulator, Y-box binding protein
1 (YB-1) [24]. As compared to AZD8055, rapamycin, an
allosteric inhibitor of mTORC1, only weakly inhibited
4E-BP1 phosphorylation and had much less repression
on Snail expression and cell invasion (Figure 3B, C
and D). Since AZD8055 also inhibited mTORC2 as
indicated by loss of p-AKT on S473 (Figure 3A, B), we
investigated whether inhibition of AKT by AZD8055 is
associated with reduction of Snail expression. Treatment
with MK2206, a selective AKT inhibitor [25], effectively
inhibited AKT phosphorylation but did not affect 4EBP1 phosphorylation, Snail expression and cell invasion
in HCT116 and MDA-468 cells (Figure 3B, C and D).
Furthermore, knockdown of rictor, a key component of
mTORC2 [26], inhibited p-AKT but had no effect on Snail
expression (Figure 3E). However, depletion of raptor,
an obligatory component of mTORC1 [27], markedly
repressed 4E-BP1 phosphorylation, Snail expression and
cell invasion (Figure 3E, F). Conversely, activation of
mTORC1 by silencing its upstream repressor TSC2 [28]
enhanced 4E-BP1 phosphorylation, Snail expression and
cell invasion (Figure 3G, H), although mTROC1 activation

Figure 2: A dominant active 4E-BP1 mutant profoundly inhibits Snail expression and cell invasion. (A) Immunoblot

analysis of HCT116 cells with stable expression of vector, HA-4E-BP1 WT or HA-4E-BP1 4A. (B, C) HCT116-4E-BP1 knockdown (KD)
cells were re-expressed with vector, HA-4E-BP1 WT or HA-4E-BP1 4A. Cell lysates were immunoblotted with the indicated antibodies
or precipitated with m7GTP sepharose beads followed by immunoblotting of HA, 4E-BP1 and eIF4E. (D) Transwell invasion analysis of
HCT116-4EBP1 KD cells with re-expressing vector, HA-4E-BP1 WT or HA-4E-BP1 4A over 30 h. The results represent the mean number
of invaded cells per field ± S.E.M. (n=3). * P < 0.02 for 4E-BP1 4A versus 4E-BP1 WT or vector.
www.impactjournals.com/oncotarget
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Figure 3: mTORC1 plays a critical role in the regulation of Snail expression and cancer cell motility. (A) HCT116 or

MDA-MB-468 cells were treated with 500 nM AZD8055 for the indicated times. Cell lysates were immunoblotted with the indicated
antibodies. (B) HCT116 or MDA-MB-468 cells were treated with 50 nM rapamycin. 500 nM AZD8055, 1 µM MK2206 or dimethyl
sulfoxide (DMSO) as control for 12 h. Cell lysates were immunoblotted with the indicated antibodies. (C, D) Transwell invasion analysis
of HCT116 and MDA-MB-468 cells in the presence of the drugs as indicated in (B) for 30 h (C) and 24 h (D), respectively. The results
represent the mean number of invaded cells per field ± S.E.M. (n=3). * P < 0.03 for AZD8055 versus DMSO control, rapamycin or
MK2206. (E) HCT116 cells alone or with stable expression of Ctrl shRNA, raptor shRNA or rictor shRNA were immunoblotted with the
indicated antibodies. (F) Transwell invasion analysis of HCT116 cells with stable expression of Ctrl shRNA or raptor shRNA over 30 h. (G)
Immunoblot analysis of HCT116 cells with stable expression of Ctrl shRNA or TSC2 shRNA. (H) Transwell invasion analysis of HCT116
cells with stable expression of Ctrl shRNA or TSC2 shRNA over 30 h. The results (F, H) represent the mean number of invaded cells per
field ± S.E.M. (n=3). # P < 0.03 for Sh raptor or Sh TSC2 versus Sh Ctrl.
www.impactjournals.com/oncotarget
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by TSC2 knockdown induced feedback inhibition of
AKT that was consistent with the previous reports
[29, 30]. Taken together, these results indicate that the
mTORC1/4E-BP1 signaling axis plays an indispensable
role in the regulation of Snail expression and migratory/
invasive capacities of cancer cells.

between 4E-BP1 knockdown and control cells (Figure
4A). However, the level of E-cadherin mRNA in the 4EBP1 knockdown cells was inhibited by about 50% (Figure
4A), which was associated with its decreased protein
expression (Figure 1B). These data suggest that 4E-BP1
translationally regulates Snail expression and secondarily
affects its transcriptional targets such as E-cadeherin.
This notion was further supported by the results showing
that downregulation of Snail protein by inhibition of
cap-dependent translation with 4E-BP1 4A (Figure 2A)
or the mTOR kinase inhibitor AZD8055 (Figure 3A, B)
was not associated with its change in the level of mRNA
(Figure 4B, C). In addition, using a cap-dependent
translation reporter luciferase (Luc) mRNA linked to
the 5’-UTR of Snail for measurement of cap-dependent
Snail translation activity, we found that the 5’-UTR of
Snail-Luc translation activity was inhibited (30-37%) by
AZD8055 in HCT116 cells or HCT116 cells expressing
control shRNA, but silencing 4E-BP1 expression that

mTORC1/4E-BP1 signaling regulates Snail
expression and its activity at the level of
translation
To understand how mTORC1/4E-BP1 signaling
regulates Snail expression, we first determined the
level of Snail mRNA by quantitative real-time reverse
transcription-PCR (RT-PCR). As compared to the
upregulation of Snail protein expression elicited by 4EBP1 knockdown in HCT116 cells (Figure 1B), there
was not a significant change in the level of Snail mRNA

Figure 4: The regulation of Snail expression by mTORC1 is through 4E-BP1-mediated cap-dependent translation
mechanism. (A) Quantitative RT-PCR analysis of mRNA expression of Snail or E-cadherin relative to β-actin in HCT116 cells with stable

expression of Ctrl shRNA or 4E-BP1 shRNA (n=3). (B) Quantitative RT-PCR analysis of mRNA expression of Snail relative to β-actin in
HCT116 cells with stable expression of vector, HA-4E-BP1 WT or HA-4E-BP1 4A (n=3). (C) Quantitative RT-PCR analysis of mRNA
expression of Snail relative to β-actin in HCT116 cells that were treated with 500 nM AZD8055 or DMSO as control for 24 h (n=3). (D)
HCT116 cells alone or with stable expression of Ctrl shRNA or 4E-BP1 shRNA were transfected with a bicistronic luciferase reporter that
detects cap-dependent translation of the Renilla luciferase gene linked to the 5’-UTR of Snail and cap-independent Polio IRES-mediated
translation of the firefly luciferase gene. The transfected cells were treated with 500 nM AZD8055 or DMSO as control for 12 h. Luciferase
activities were measured by a dual-luciferase assay, and the Renilla/firefly luciferase luminescence ratio was calculated for cap-dependent
translational activity. The results are expressed as the inhibition of cap-dependent translation relative to the DMSO-treated controls and
presented as means ± S.E.M. (n=3). (E) Immunoblot analysis of HCT116 cells with stable expression of Ctrl shRNA or 4E-BP1 shRNA that
were treated with or without 500 nM AZD8055 for 12 h. (F) HCT116 cells were treated with 500 nM AZD8055 or DMSO as control for
30 min, followed by addition of 20 µg/ml cycloheximide (CHX) for the indicated times. Cell lysates were immunoblotted with Snail and
β-actin antibodies. (G) Immunoblots of Snail as shown in (F) were quantified using the FluorChem digital imaging system (Alpha Innotech,
Santa Clara, CA). The level of Snail remaining was obtained by normalizing β-actin level at each time, and the results are presented as mean
± S.E.M. (n=3). * P < 0.03 for Sh 4E-BP1 versus Sh Ctrl.
www.impactjournals.com/oncotarget
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Figure 5: Snail is an important effector of mTORC1/4E-BP1 signaling responsible for translational control of cancer
cell migration and invasion. (A) Immunoblot analysis of HCT116 cells with expression of vector or HA-tagged Snail. (B, C) Migration
(B) or invasion (C) analysis of HCT116 cells with expression of vector or Snail. (D) Invasion analysis of HCT116 cells with expression
of vector or Snail in the presence of 500 nM AZD8055 or DMSO as control for 30 h. (E) Invasion analysis of HCT116 cells with stable
expression of control shRNA, raptor shRNA or raptor shRNA with co-expressing Snail over 30 h. (F) Invasion analysis of HCT116 cells
with stable expression of vector, 4E-BP1 4A or 4E-BP1 4A with co-expressing Snail over 30 h. (G, H) HCT116 cells with stable expression
of Ctrl shRNA or 4E-BP1 shRNA were transfected with control siRNA or Snail siRNA for 48 hours, followed by immunoblot analysis with
the indicated antibodies (G) and invasion analysis over 30 h (H). Data shown in graphs represent the mean ± S.E.M. (n=3). * P < 0.02.

Figure 6: The translation initiation inhibitor 4EGI-1 effectively suppresses Snail expression and migratory and invasive
capacities of cancer cells. (A) Immunoblot analyses of the indicated cells that were treated with 50 µM 4EGI-1 for the indicated times.

(B) Quantitative RT-PCR analysis of mRNA expression of Snail relative to β-actin in the indicated cells that were treated with 50 µM 4EGI1 or DMSO as control for 24 h (n=3). (C) Migration analysis of HCT116 cells in the presence of 4EGI-1 with the indicated concentrations
for 6 h. (D) Invasion analysis of HCT116, MDA-MB-468 and MDA-MB-231 cells in the presence of 50 µM 4EGI-1 or DMSO as control
for 30 h, 24 h and 20h, respectively. (E) Invasion analysis of HCT116 cells with expression of vector or Snail in the presence of 50 µM
4EGI-1 or DMSO as control for 30 h. Data shown in graphs represent the mean ± S.E.M. (n=3). * P < 0.03.
www.impactjournals.com/oncotarget
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activates cap-dependent translation significantly rescued
the inhibitory effect (Figure 4D). Moreover, knockdown
of 4E-BP1 expression markedly reversed the decreased
expression of Snail protein attendant with the increased
expression of E-cadherin, and reduced the inhibitory
effect of AZD8055 on cell invasion (Figure 4E and
Supplementary Figure 4). Additionally, we found that the
decreased Snail expression by AZD8055 was not due to
the change in its protein stability as analyzed by protein
degradation rate using cycloheximide chase assay (Figure
4F, G). Collectively, these data indicate that mTORC1
regulates Snail expression and its activity largely through
4E-BP1-mediated cap-dependent translation mechanism.

raptor knockdown on suppression of cell invasion was
profoundly reduced compared with that in the control
cells (Figure 5D, E). In addition, overexpression of Snail
could also reverse a decreased cell invasion induced by
the cap-dependent translation inhibitor 4E-BP1 4A (Figure
5F). Conversely, silencing Snail expression 48 h after
transfection with siRNA markedly inhibited cell invasion
in both control and 4E-BP1 knockdown cells, although
4E-BP1 knockdown upregulated Snail expression and
promoted cell invasion (Figure 5G, H). Thus, these data
suggest that Snail plays a critical role in mediating the
effects of mTORC1/4E-BP1 signaling on translational
control of cell migration and invasion.

Snail mediates the effects of mTORC1/4E-BP1
signaling on translational control of cancer cell
migration and invasion

Targeting translation initiation with 4EGI-1
blocks Snail expression and cancer cell migration
and invasion

The importance of Snail downregulation in
mediating the effects of the mTORC1/4E-BP1 pathway
inhibition was determined in HCT116 cells in which Snail
protein was exogenously overexpressed (Figure 5A).
These cells did not exhibit changes in cell proliferation
(data not shown) but showed a two- to three-fold increase
in cell migration and invasion compared with the vector
control cells (Figure 5B, C). Furthermore, in these cells,
the effect of mTROC1 inhibition elicited by AZD8055 or

To further confirm that the cap-dependent translation
is required for Snail expression, a selective eIF4E/eIF4G
interaction inhibitor, 4EGI-1 that blocks assembly of
eIF4F translation initiation complex [31], was tested
in HCT116, MDA-MB-468 and MDA-MB-231 cells.
As shown in Figure 6A, 4EGI-1 inhibited Snail protein
expression in all three cell lines 12 h after drug exposure
and profoundly by 24 h. However, the level of Snail
mRNA was unaffected by 4EGI-1 (Figure 6B). Similar
to the findings obtained from mTORC1 inhibition or
repression of cap-dependent translation by 4E-BP1 4A on
cell motility (Figures 2 and 3), 4EGI-1 could also inhibit
cancer cell migration in a dose dependent manner (Figure
6C). Furthermore, 4EGI-1 markedly inhibited invasive
capability of HCT116, MDA-MB-468 and MDA-MB-231
cells (Figure 6D), but overexpression of Snail could
largely prevent the inhibitory effects (Figure 6E). These
data suggest that exploring a small molecular inhibitor to
directly target eIF4F translation initiation complex could
represent an alternative strategy for suppression of Snail
expression and metastatic potential of cancer.

DISCUSSION
In this study, we provide substantial evidence
to support the notion that the 4E-BP1-regulated capdependent translation plays an active role in EMT
induction, tumor cell migration and invasion via the
selective increased translation of Snail accompanied by
its transcriptional repression of E-cadherin expression.
Our study demonstrates a distinctive mechanism for the
regulation of Snail and its activities in the process of
cancer metastasis.
Migration and invasion are critical steps in the
initial progression of cancer that facilitate metastasis.
Emerging evidence shows that Snail-induced EMT
via downregulation of E-cadherin is associated with

Figure 7: A schematic model for the role of
mTROC1/4E-BP1 signaling axis in the translational
control of Snail and its biological consequences.
Arrowheads represent activation; bar-headed lines represent
inhibition. * mutation.
www.impactjournals.com/oncotarget
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increased migratory and invasive capabilities, and the
subsequent systemic spread of cancer cells [14, 15].
The expression of Snail has been shown to correlate
significantly with disease relapse and poor prognosis in
patients with breast, colorectal and ovarian carcinomas
[12-15]. Many studies have demonstrated that Snail
is tightly regulated at the transcriptional level by an
integrated and complex signaling network including the
PI3K/AKT, RAS/RAF/MEK/ERK, RhoGD12, TGFβ/
Smad, Notch, Wnt/β-catenin and NFκB pathways [16, 32].
In addition, expression of Snail and its function are also
shown to be regulated by posttranslational modifications.
GSK-3β, negatively regulated by AKT, has been shown to
phosphorylate Snail, leading to its subcellular localization
and degradation [17]. Early studies showed that inhibition
of PI3K/AKT signaling with the PI3K inhibitors,
wortmannin and LY294002, release the suppression of
GSK-3β, which leads to subsequent degradation of Snail
[17, 33]. However, using the selective AKT inhibitor
MK2206 as we and others reported previously [19, 25], we
found that inhibition of AKT has no effect on Snail mRNA
and protein expression in colon and breast cancer cells
(Figure 3B and Supplementary Figure 5). These findings
are further confirmed by silencing the AKT upstream
regulator, rictor (Figure 3E). Given that wortmannin and
LY294002 can also inhibit other PI3K-related enzymes
such as mTOR [34, 35], it is thus reasonable to speculate
that mTOR may involve in the regulation of Snail
expression and its activity. Our data show that Snail,
but not other EMT inducers such as Slug and Twist, is
specifically downregulated with concomitant increased
expression of E-cadherin by the pharmacologic or genetic
inhibition of mTORC1, whereas aberrant activation of
mTORC1 by TSC2 knockdown exhibits opposite effect.
Notably, the decreased expression of Snail by mTORC1
inhibition is not associated with changes in the level of
transcription or protein stability. Mechanistically, we
identify that the cap-dependent translation repressor 4EBP1 functions as a key effector of mTROC1 activation on
translational control of Snail expression and its subsequent
activities as noted by the transcriptional repression of
E-cadherin, induction of EMT and promotion of migration
and invasion in colon and breast cancer cells (Figure 7). In
addition, disruption of cap-dependent translation initiation
complex with the selective eIF4E/eIF4G interaction
inhibitor 4EGI-1 shows a profound inhibition on Snail
expression as well as migratory and invasive abilities of
cancer cells. Thus, our findings indicate that Snail activity
could be regulated in AKT-independent but mTORC1/4EBP1-mediated cap-dependent translation initiation
mechanism.
A recent report by Evdokimova and colleagues
[24] suggested that YB-1 is positively involved in the
regulation of Snail expression via cap-independent
translation associated with breast cancer aggressiveness,
as they showed that inhibition of mTORC1-mediated
www.impactjournals.com/oncotarget

cap-dependent translation with rapamycin does not affect
Snail levels in YB-1-expressing premalignant MCF10AT
human mammary epithelial cells. YB-1 is highly
expressed in multiple human malignancies including
breast and colorectal cancers [36]. Although our data
also show that rapamycin has negligible effect on Snail
expression and cell invasion in breast and colon cancer
cells, we found that the insignificant effect is associated
with the weak inhibition of mTORC1-mediated 4E-BP1
phosphorylation by rapamycin. First, we showed that as
compared with rapamycin, both mTOR kinase inhibitor
AZD8055 and/or specific inhibition of mTORC1 by
raptor knockdown exhibit potent inhibition of 4E-BP1
phosphorylation; and both also effectively repress Snail
expression and its subsequent activities in colon and breast
cancer cell lines with highly expressed YB-1 (Figure 3).
Second, the non-phosphorylated mutant 4E-BP1-4A
with constitutive inhibition of cap-dependent translation
also profoundly inhibits Snail expression and cell
motility (Figure 2), as well as colon cancer metastasis,
as we reported recently[19]. Third, silencing 4E-BP1
expression significantly rescues translational inhibition of
Snail and cell invasion by AZD8055 (Figure 4D, E and
Supplementary Figure 4). More importantly, the decreased
level of Snail by mTORC1 inhibition is not associated
with changes in the level of YB-1 expression (Figure
3A and Supplementary Figure 3). Taken together, these
data further support the conclusion that mTORC1/4EBP1 signaling plays a crucial role in the cap-dependent
translational regulation of Snail and its biologic
consequences during the metastatic progression of cancer.
Our findings are consistent with recent reports [3739] showing the role of mTORC1 in the EMT process
and translational control of gene expression program
for cancer progression. However, a more recent study
reported conflicting results. Using normal immortalized
human epithelial cell lines and primary epithelial cells,
Mikaelian and colleagues [40] showed that genetic and
pharmacologic inhibition of mTORC1 triggers EMT
associated with upregulation of ZEB1, known to activate
EMT, but these effects are not found in cancer-driven cell
lines including the MDA-MB-231 breast cancer cell line
as we used in this study. Indeed, we found that mTORC1
inhibition represses EMT process in colon and breast
cancer cells by specific inhibition of Snail translation
attendant with increased expression of the epithelial
marker E-cadherin, thus suppressing cancer cell migration
and invasion. This discordant effect of mTORC1 inhibition
on EMT and cell motility is probably dependent on the
mutational status of the cells. Mutations in genes that
encode components of the PI3K/AKT and RAS/RAF/
MEK/ERK pathways occur at high frequency in cancers
including colon and breast cancers [41-43]. We and others
have recently shown that mTORC1/4E-BP1 axis largely
mediates the effects of the mutational activation of AKT
and ERK signaling pathways on translational control of
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cancer cell motility and metastasis[19] [11, 39]. Thus, it
is possible that tumors with mutational activation of AKT
and ERK pathways are highly dependent on mTORC1/4EBP1 signaling for the promotion of EMT, cell motility
and metastasis (Figure 7). Our data suggest that targeting
mTROC1 with the ATP-site mTOR kinase inhibitors
that can effectively activate 4E-BP1 repressive function
on cap-dependent translation may provide a promising
treatment strategy for blocking metastatic progression of
cancer. Many mTOR kinase inhibitors are in early clinical
testing. The anti-metastatic effect of these inhibitors and
their potential side effect on EMT induction in normal
cells should now be evaluated in detail in the clinical
studies.
Our results also suggest that directly targeting
assembly of eIF4F translation initiation complex
(Figure 6) may be an effective alternative to the mTOR
kinase inhibitors or combination of AKT and MEK
kinase inhibitors as we showed recently [11, 19]. Given
the importance of 4E-BP1-regulated cap-dependent
translation as a common downstream node that integrates
multiple oncogenic signaling pathways for tumor growth
and metastasis [11, 19, 44], compounds that mimic 4EBP1 biochemical function by disruption of eIF4E-eIF4G
interaction or target other translation initiation components
may be effective for cancer therapeutics. Indeed, several
of those translation initiation inhibitors, including eIF4E
antisense-oligonucleotides and silvestrol that inhibits the
RNA helicase eIF4A, have recently produced encouraging
anti-tumor effects with limited toxicity profiles in mouse;
and some of these inhibitors have been tested in clinical
studies [45-48]. Considering an accumulation of damaging
side effects from a combination of therapies that inhibits
several canonical signaling pathways impinging upon
translation initiation, and the mTOR inhibition-induced
feedback activation of upstream receptors and AKT
signaling that may reduce anti-tumor effects of mTOR
inhibitors [49-52], targeting cap-dependent translation
that could simultaneously block upstream oncogenic
signals and their downstream targets would hold potential
as a future therapeutic strategy against the metastatic
progression of cancer.

and rictor shRNA expression plasmids were purchased
from Addgene (Cambridge, MA). The specificity of the
targeting raptor and rictor sequences has been verified
and described previously [26]. The human 4E-BP1 and
TSC2 shRNA expression plasmids were from Open
Biosystems (Lafayette, CO) and the specificity of the
targeting sequences has been verified in our previous
study [19]. siRNA pool against human Snail (L-010847)
or non-targeting control siRNA pool (D-001810-10) was
obtained from Dharmacon (Chicago, IL). For establishing
stable transfectants with knockdown of specific protein
expression, cell lines were lentivirally infected with the
indicated shRNA construct followed by selection with
puromycin (2 µg/ml) for one week. HCT116 or HCT1164E-BP1 knockdown cells with stable expression of
HA-tagged 4E-BP1 and 4E-BP1-4A were generated as
described previously [11].

MATERIALS AND METHODS

Cells were lysed in NP-40 lysis buffer as described
previously [11]. Equal amounts of total protein were
resolved by SDS-PAGE, transferred to membranes,
immunoblotted with specific primary and secondary
antibodies and detected using chemiluminescence (GE
Healthcare Bio-Sciences, Pittsburgh, PA). Antibodies for
p-AKT(S473), p-4E-BP1(T37/46), p-4E-BP1(S65), p-4EBP1(T70), 4E-BP1, eIF4E, Snail, Slug, YB-1, raptor,
rictor and TSC2 were from Cell Signaling Technology
(Danvers, MA). E-cadherin antibody (67A4) was from
Santa Cruz Biotechnology (Dallas, TX). HA antibody
was from Novus Biologicals (Littleton, CO) and -actin
antibody was from Sigma (St Louis, MO).

Migration and invasion assays
Migration and invasion assays were performed
in Boyden chambers with coated collagen or Matrigel,
respectively, as instructed by the manufacturer (BD
Biosciences, San Jose, CA) and described previously
[19]. Briefly, cells were added to the upper chamber of
the transwell insert. Completed medium containing 10%
FBS as chemoattractant was added to the bottom chamber.
To assess the effect of kinase inhibitors on cell migration
and invasion, the inhibitors or their vehicle control DMSO
were added to the bottom chamber medium. The plates
were incubated at 37°C in 5% CO2 for indicated time
points. After incubation, cells in the upper compartment
were removed with a cotton swab, and cells that migrated
or invaded to the filter surface facing the bottom chamber
were fixed in 4% paraformaldehyde and stained with 0.2%
crystal violet. The numbers of migrated or invaded cells
were counted in at least four areas at x 40 magnification
using an inverted microscope. All experiments were
performed at least twice in triplicate.

Immunoblot analysis

Cell culture, plasmids, siRNA and shRNA
Human colon and breast cancer cell lines were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and maintained in the appropriate
medium with supplements as suggested by ATCC.
MK2206, rapamycin and AZD8055 were obtained from
Selleck (Houston, TX). The pcDNA3.1-HA-tagged
human Snail expression plasmid and the human raptor
www.impactjournals.com/oncotarget
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Quantitative RT-PCR

dependent translational activity.

Animal studies

Total cellular RNA was isolated using the RNeasy
plus mini kit (Qiagen, Valencia, CA). Equal amounts of
RNA were used as templates for all reactions. Doublestranded cDNA was generated by using the SuperScript III
First Strand Synthesis System (Life Technologies, Grand
Island, NY). Real-time PCR reactions were carried out
with specific probes for human Snail (Hs00195591_m1),
E-cadherin (Hs01023894_m1) and β-actin (#4352935E)
using the StepOne Real-Time PCR system (Applied
Biosystems, Foster City, CA).

Male athymic nude mice (5-6 weeks old) were
purchased from Taconic (Hudson, NY, USA) and
maintained and treated under specific pathogen-free
conditions. The experimental liver metastasis assay was
described previously [19]. Briefly, cells with co-expression
of firefly luciferase and GFP were injected into the spleen
(5×106/mouse) of athymic nude mice (n=6 per group).
To monitor metastasis, mice were imaged with luciferase
signals using the IVIS Spectrum (Caliper Life Science,
Hopkinton, MA, USA) and results were analyzed by
Living Image 3.0 software. In addition, the liver metastatic
lesions were further examined by GFP imaging.

Cycloheximide (CHX) chase assay
Cells were treated with CHX (20 µg/ml) and
harvested at indicated time points. The cells were lysed in
NP-40 lysis buffer and equal amounts of total protein were
analyzed by immunoblot. To examine the effect of mTOR
inhibition, one set of cells was pretreated with AZD8055
for 30 min before the addition of CHX.

Statistical analysis
All experiments were carried out in at least twice.
Results are expressed as mean ± S.E.M. where applicable.
A two-tailed Student’s t-test was used to compare the
intergroup. Differences between groups were considered
statistically significant at P < 0.05.

Cap-Binding Assay
Cell lysates as prepared above were incubated with
m7GTP sepharose beads (GE Healthcare Bio-Sciences)
to capture eIF4E and its binding partners. Precipitates
were washed three times with lysis buffer, resuspended in
2x Laemmli sample buffer, and resolved by SDS-PAGE
followed by immunoblot with the indicated antibodies.
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